Waters buys charge detection mass spectrometry technology

Waters Corporation has acquired the technology assets and intellectual property rights of Megadalton Solutions, Inc., an early-stage developer of Charge Detection Mass Spectrometry (CDMS) technology and services. Megadalton Solutions has developed CDMS instrumentation that makes it possible to analyse extremely large proteins and protein complexes, such as those used in cell and gene therapies, that would otherwise be difficult to analyse with conventional mass spectrometry. Waters became a strategic investor in the company and in 2021 brought Megadalton’s CDMS technology into the Waters Immerse Cambridge innovation and research lab for advanced testing and development. Large molecule mass spectrometry with CDMS offers an important tool for the characterisation, analysis and quantification of next-generation biologics, such as cell and gene therapies, which is an area of high interest among biopharmaceutical and biomedical research customers.